FIELD: biotechnology.
SUBSTANCE: described are a humanised monoclonal antibody selectively binding to the human PRAME tumour antigen, as well as DNA fragments encoding sections of the light and heavy chains of said antibody, and an antigen-binding fragment of said humanised monoclonal antibody.
EFFECT: invention provides a possibility of producing a new humanised monoclonal antibody of the IgG1 isotype, capable of binding to the human PRAME tumour antigen, and characterised by the antigen-antibody complex dissociation constant of 1.2 nM.
4 cl, 7 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| ANTIBODIES DIRECTED AT EPITOPES LOCATED IN AREA OF 160-200 AMINO ACID BASES OF HUMAN PRAME PROTEIN, AND THEIR APPLICATION | 2019 |
|
RU2774194C2 |
| NEUTRALIZING MONOCLONAL ANTIBODY BINDING TO RABIES VIRUS GLYCOPROTEIN G, DNA FRAGMENTS CODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2017 |
|
RU2718835C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2639533C2 |
| MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT | 2015 |
|
RU2630304C2 |
| PREPARATION BASED ON NEUTRALIZING MONOCLONAL ANTIBODIES BINDING WITH GLYCOPROTEIN OF RABIES VIRUS | 2018 |
|
RU2711553C1 |
| MONOCLONAL ANTIBODY, LINKING WITH E-BIR VIRUS GLOBE-PROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2016 |
|
RU2644334C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
